
Shares of drugmaker Vanda Pharmaceuticals VNDA.O rise 17% to $5.15 in early trading
Stock set for its biggest percent gain in over five months
Co says its experimental drug tradipitant significantly reduces nausea and vomiting in people taking the popular weight-loss drug Wegovy, according to results from a new clinical trial
Study met main goal, 29.3% on tradipitant vomited vs 58.6% on placebo; also reduced severe nausea - VNDA
Co says late-stage trial planned for 2026
GLP-1 market exceeds $50 bln globally; tradipitant could boost adherence - VNDA
Including session's move, stock up ~7% YTD